Literature DB >> 3262832

Functional replacement of the HIV-1 rev protein by the HTLV-1 rex protein.

L Rimsky1, J Hauber, M Dukovich, M H Malim, A Langlois, B R Cullen, W C Greene.   

Abstract

Two evolutionarily distinct families of human retroviruses, the human immunodeficiency viruses (HIV) and the human T-cell leukaemia viruses (HTLV), have been defined (reviewed in ref. 1). Although these virus groups share tropism for human CD4+ T cells, they differ markedly in primary sequence, genetic organization and disease association (AIDS versus adult T-cell leukaemia), but show similar general strategies for the regulation of viral gene expression. Each encodes a protein able to trans-activate transcription from the homologous viral long terminal repeat (tat in HIV, tax in HTLV), although these proteins act by different mechanisms and do not appear to be interchangeable. Each virus also produces a second trans-acting protein that induces the expression of the unspliced messenger RNAs encoding the viral structural proteins (rev in HIV and rex in HTLV). Here we show that the rex protein of HTLV-I can functionally replace the rev protein of HIV-1 in transient expression assays. This genetic complementation by rex is adequate for the rescue of a replication-defective rev mutant of HIV-1. This unexpected shared function between the structurally distinct rex and rev proteins emphasizes the importance of this highly conserved pathway for the regulation of human retrovirus gene expression.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3262832     DOI: 10.1038/335738a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  97 in total

1.  Anti-Rex aptamers as mimics of the Rex-binding element.

Authors:  S Baskerville; M Zapp; A D Ellington
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

2.  Rec (formerly Corf) function requires interaction with a complex, folded RNA structure within its responsive element rather than binding to a discrete specific binding site.

Authors:  C Magin-Lachmann; S Hahn; H Strobel; U Held; J Löwer; R Löwer
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

3.  The v-rel oncogene: insights into the mechanism of transcriptional activation, repression, and transformation.

Authors:  W H Walker; B Stein; P A Ganchi; J A Hoffman; P A Kaufman; D W Ballard; M Hannink; W C Greene
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

Review 4.  Mechanism of action of regulatory proteins encoded by complex retroviruses.

Authors:  B R Cullen
Journal:  Microbiol Rev       Date:  1992-09

5.  Posttranscriptional regulation by the human immunodeficiency virus type 1 Rev and human T-cell leukemia virus type I Rex proteins through a heterologous RNA binding site.

Authors:  D McDonald; T J Hope; T G Parslow
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

6.  Specific binding of the human T-cell leukemia virus type I Rex protein to a short RNA sequence located within the Rex-response element.

Authors:  H P Bogerd; L S Tiley; B R Cullen
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

7.  trans activation of the tumor necrosis factor alpha promoter by the human T-cell leukemia virus type I Tax1 protein.

Authors:  H Albrecht; A N Shakhov; C V Jongeneel
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

8.  Early transcription from nonintegrated DNA in human immunodeficiency virus infection.

Authors:  Yuntao Wu; Jon W Marsh
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Selective infection of human T-lymphotropic virus type 1 (HTLV-1)-infected cells by chimeric human immunodeficiency viruses containing HTLV-1 tax response elements in the long terminal repeat.

Authors:  H C Lin; M Bodkin; R B Lal; A B Rabson
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

10.  Nucleolar localization of myc transcripts.

Authors:  V C Bond; B Wold
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.